The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Ondansetron (CAS 99614-02-5) Market Research Report 2024
Synopsis
Ondansetron (CAS 99614-02-5), C18H19N3O, the formula weight is 293.36, and its form is white crystal.
Ondansetron is a highly selective serotonin (5-HT3) receptor antagonist that inhibits nausea and vomiting caused by chemotherapy and radiotherapy. It has high strength and high selectivity and can control small intestine and CTZ. The vomiting and vomiting caused by the stimulation of the receptor. It is suitable for the treatment of nausea and vomiting caused by chemotherapy and radiotherapy. It can also be used to prevent and treat nausea and vomiting caused by surgery.
The global Ondansetron (CAS 99614-02-5) market was valued at US$ XX million in 2019 and is expected to reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
This report focuses on Ondansetron (CAS 99614-02-5) volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Ondansetron (CAS 99614-02-5) market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Ondansetron (CAS 99614-02-5) Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Ondansetron Hydrochloride Tablets
Ondansetron Hydrochloride Capsule
Ondansetron Hydrochloride Injection
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Qilu Pharma
CSPC
Fuan Pharma
GSK
PKU HealthCare
Sino-Pharma
Aosaikang Pharma
Zhongbao Pharma
Wockhardt
Sun Pharma
Aelida Healthcare
Hospira
Drums Healthcare
SANDOZ
Ondansetron (CAS 99614-02-5), C18H19N3O, the formula weight is 293.36, and its form is white crystal.
Ondansetron is a highly selective serotonin (5-HT3) receptor antagonist that inhibits nausea and vomiting caused by chemotherapy and radiotherapy. It has high strength and high selectivity and can control small intestine and CTZ. The vomiting and vomiting caused by the stimulation of the receptor. It is suitable for the treatment of nausea and vomiting caused by chemotherapy and radiotherapy. It can also be used to prevent and treat nausea and vomiting caused by surgery.
The global Ondansetron (CAS 99614-02-5) market was valued at US$ XX million in 2019 and is expected to reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
This report focuses on Ondansetron (CAS 99614-02-5) volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Ondansetron (CAS 99614-02-5) market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Ondansetron (CAS 99614-02-5) Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Ondansetron Hydrochloride Tablets
Ondansetron Hydrochloride Capsule
Ondansetron Hydrochloride Injection
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Qilu Pharma
CSPC
Fuan Pharma
GSK
PKU HealthCare
Sino-Pharma
Aosaikang Pharma
Zhongbao Pharma
Wockhardt
Sun Pharma
Aelida Healthcare
Hospira
Drums Healthcare
SANDOZ
Index1 Ondansetron (CAS 99614-02-5) Market Overview
1.1 Product Overview and Scope of Ondansetron (CAS 99614-02-5)
1.2 Ondansetron (CAS 99614-02-5) Segment by Type
1.2.1 Global Ondansetron (CAS 99614-02-5) Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Ondansetron Hydrochloride Tablets
1.2.3 Ondansetron Hydrochloride Capsule
1.2.4 Ondansetron Hydrochloride Injection
1.2.5 Others
1.3 Ondansetron (CAS 99614-02-5) Segment by Application
1.3.1 Ondansetron (CAS 99614-02-5) Sales Comparison by Application: (2021-2027)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Ondansetron (CAS 99614-02-5) Market Size Estimates and Forecasts
1.4.1 Global Ondansetron (CAS 99614-02-5) Revenue 2016-2027
1.4.2 Global Ondansetron (CAS 99614-02-5) Sales 2016-2027
1.4.3 Ondansetron (CAS 99614-02-5) Market Size by Region: 2016 Versus 2021 Versus 2027
2 Ondansetron (CAS 99614-02-5) Market Competition by Manufacturers
2.1 Global Ondansetron (CAS 99614-02-5) Sales Market Share by Manufacturers (2016-2021)
2.2 Global Ondansetron (CAS 99614-02-5) Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Ondansetron (CAS 99614-02-5) Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Ondansetron (CAS 99614-02-5) Manufacturing Sites, Area Served, Product Type
2.5 Ondansetron (CAS 99614-02-5) Market Competitive Situation and Trends
2.5.1 Ondansetron (CAS 99614-02-5) Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Ondansetron (CAS 99614-02-5) Players Market Share by Revenue
2.5.3 Global Ondansetron (CAS 99614-02-5) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Ondansetron (CAS 99614-02-5) Retrospective Market Scenario by Region
3.1 Global Ondansetron (CAS 99614-02-5) Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Ondansetron (CAS 99614-02-5) Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Ondansetron (CAS 99614-02-5) Market Facts & Figures by Country
3.3.1 North America Ondansetron (CAS 99614-02-5) Sales by Country
3.3.2 North America Ondansetron (CAS 99614-02-5) Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Ondansetron (CAS 99614-02-5) Market Facts & Figures by Country
3.4.1 Europe Ondansetron (CAS 99614-02-5) Sales by Country
3.4.2 Europe Ondansetron (CAS 99614-02-5) Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Ondansetron (CAS 99614-02-5) Market Facts & Figures by Region
3.5.1 Asia Pacific Ondansetron (CAS 99614-02-5) Sales by Region
3.5.2 Asia Pacific Ondansetron (CAS 99614-02-5) Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Ondansetron (CAS 99614-02-5) Market Facts & Figures by Country
3.6.1 Latin America Ondansetron (CAS 99614-02-5) Sales by Country
3.6.2 Latin America Ondansetron (CAS 99614-02-5) Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Ondansetron (CAS 99614-02-5) Market Facts & Figures by Country
3.7.1 Middle East and Africa Ondansetron (CAS 99614-02-5) Sales by Country
3.7.2 Middle East and Africa Ondansetron (CAS 99614-02-5) Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Ondansetron (CAS 99614-02-5) Historic Market Analysis by Type
4.1 Global Ondansetron (CAS 99614-02-5) Sales Market Share by Type (2016-2021)
4.2 Global Ondansetron (CAS 99614-02-5) Revenue Market Share by Type (2016-2021)
4.3 Global Ondansetron (CAS 99614-02-5) Price by Type (2016-2021)
5 Global Ondansetron (CAS 99614-02-5) Historic Market Analysis by Application
5.1 Global Ondansetron (CAS 99614-02-5) Sales Market Share by Application (2016-2021)
5.2 Global Ondansetron (CAS 99614-02-5) Revenue Market Share by Application (2016-2021)
5.3 Global Ondansetron (CAS 99614-02-5) Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Qilu Pharma
6.1.1 Qilu Pharma Corporation Information
6.1.2 Qilu Pharma Description and Business Overview
6.1.3 Qilu Pharma Ondansetron (CAS 99614-02-5) Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Qilu Pharma Product Portfolio
6.1.5 Qilu Pharma Recent Developments/Updates
6.2 CSPC
6.2.1 CSPC Corporation Information
6.2.2 CSPC Description and Business Overview
6.2.3 CSPC Ondansetron (CAS 99614-02-5) Sales, Revenue and Gross Margin (2016-2021)
6.2.4 CSPC Product Portfolio
6.2.5 CSPC Recent Developments/Updates
6.3 Fuan Pharma
6.3.1 Fuan Pharma Corporation Information
6.3.2 Fuan Pharma Description and Business Overview
6.3.3 Fuan Pharma Ondansetron (CAS 99614-02-5) Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Fuan Pharma Product Portfolio
6.3.5 Fuan Pharma Recent Developments/Updates
6.4 GSK
6.4.1 GSK Corporation Information
6.4.2 GSK Description and Business Overview
6.4.3 GSK Ondansetron (CAS 99614-02-5) Sales, Revenue and Gross Margin (2016-2021)
6.4.4 GSK Product Portfolio
6.4.5 GSK Recent Developments/Updates
6.5 PKU HealthCare
6.5.1 PKU HealthCare Corporation Information
6.5.2 PKU HealthCare Description and Business Overview
6.5.3 PKU HealthCare Ondansetron (CAS 99614-02-5) Sales, Revenue and Gross Margin (2016-2021)
6.5.4 PKU HealthCare Product Portfolio
6.5.5 PKU HealthCare Recent Developments/Updates
6.6 Sino-Pharma
6.6.1 Sino-Pharma Corporation Information
6.6.2 Sino-Pharma Description and Business Overview
6.6.3 Sino-Pharma Ondansetron (CAS 99614-02-5) Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Sino-Pharma Product Portfolio
6.6.5 Sino-Pharma Recent Developments/Updates
6.7 Aosaikang Pharma
6.6.1 Aosaikang Pharma Corporation Information
6.6.2 Aosaikang Pharma Description and Business Overview
6.6.3 Aosaikang Pharma Ondansetron (CAS 99614-02-5) Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Aosaikang Pharma Product Portfolio
6.7.5 Aosaikang Pharma Recent Developments/Updates
6.8 Zhongbao Pharma
6.8.1 Zhongbao Pharma Corporation Information
6.8.2 Zhongbao Pharma Description and Business Overview
6.8.3 Zhongbao Pharma Ondansetron (CAS 99614-02-5) Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Zhongbao Pharma Product Portfolio
6.8.5 Zhongbao Pharma Recent Developments/Updates
6.9 Wockhardt
6.9.1 Wockhardt Corporation Information
6.9.2 Wockhardt Description and Business Overview
6.9.3 Wockhardt Ondansetron (CAS 99614-02-5) Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Wockhardt Product Portfolio
6.9.5 Wockhardt Recent Developments/Updates
6.10 Sun Pharma
6.10.1 Sun Pharma Corporation Information
6.10.2 Sun Pharma Description and Business Overview
6.10.3 Sun Pharma Ondansetron (CAS 99614-02-5) Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Sun Pharma Product Portfolio
6.10.5 Sun Pharma Recent Developments/Updates
6.11 Aelida Healthcare
6.11.1 Aelida Healthcare Corporation Information
6.11.2 Aelida Healthcare Ondansetron (CAS 99614-02-5) Description and Business Overview
6.11.3 Aelida Healthcare Ondansetron (CAS 99614-02-5) Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Aelida Healthcare Product Portfolio
6.11.5 Aelida Healthcare Recent Developments/Updates
6.12 Hospira
6.12.1 Hospira Corporation Information
6.12.2 Hospira Ondansetron (CAS 99614-02-5) Description and Business Overview
6.12.3 Hospira Ondansetron (CAS 99614-02-5) Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Hospira Product Portfolio
6.12.5 Hospira Recent Developments/Updates
6.13 Drums Healthcare
6.13.1 Drums Healthcare Corporation Information
6.13.2 Drums Healthcare Ondansetron (CAS 99614-02-5) Description and Business Overview
6.13.3 Drums Healthcare Ondansetron (CAS 99614-02-5) Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Drums Healthcare Product Portfolio
6.13.5 Drums Healthcare Recent Developments/Updates
6.14 SANDOZ
6.14.1 SANDOZ Corporation Information
6.14.2 SANDOZ Ondansetron (CAS 99614-02-5) Description and Business Overview
6.14.3 SANDOZ Ondansetron (CAS 99614-02-5) Sales, Revenue and Gross Margin (2016-2021)
6.14.4 SANDOZ Product Portfolio
6.14.5 SANDOZ Recent Developments/Updates
7 Ondansetron (CAS 99614-02-5) Manufacturing Cost Analysis
7.1 Ondansetron (CAS 99614-02-5) Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Ondansetron (CAS 99614-02-5)
7.4 Ondansetron (CAS 99614-02-5) Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Ondansetron (CAS 99614-02-5) Distributors List
8.3 Ondansetron (CAS 99614-02-5) Customers
9 Ondansetron (CAS 99614-02-5) Market Dynamics
9.1 Ondansetron (CAS 99614-02-5) Industry Trends
9.2 Ondansetron (CAS 99614-02-5) Growth Drivers
9.3 Ondansetron (CAS 99614-02-5) Market Challenges
9.4 Ondansetron (CAS 99614-02-5) Market Restraints
10 Global Market Forecast
10.1 Ondansetron (CAS 99614-02-5) Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Ondansetron (CAS 99614-02-5) by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Ondansetron (CAS 99614-02-5) by Type (2022-2027)
10.2 Ondansetron (CAS 99614-02-5) Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Ondansetron (CAS 99614-02-5) by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Ondansetron (CAS 99614-02-5) by Application (2022-2027)
10.3 Ondansetron (CAS 99614-02-5) Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Ondansetron (CAS 99614-02-5) by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Ondansetron (CAS 99614-02-5) by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of TablesList of Tables
Table 1. Global Ondansetron (CAS 99614-02-5) Sales (Kg) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Ondansetron (CAS 99614-02-5) Sales (Kg) Comparison by Application (2021-2027)
Table 3. Global Ondansetron (CAS 99614-02-5) Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Ondansetron (CAS 99614-02-5) Covered in This Study
Table 5. Global Ondansetron (CAS 99614-02-5) Sales (Kg) of Key Manufacturers (2016-2021)
Table 6. Global Ondansetron (CAS 99614-02-5) Sales Share by Manufacturers (2016-2021)
Table 7. Global Ondansetron (CAS 99614-02-5) Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Ondansetron (CAS 99614-02-5) Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Ondansetron (CAS 99614-02-5) Average Price (USD/Kg) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Ondansetron (CAS 99614-02-5) Manufacturing Sites and Area Served
Table 11. Manufacturers Ondansetron (CAS 99614-02-5) Product Type
Table 12. Global Ondansetron (CAS 99614-02-5) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Ondansetron (CAS 99614-02-5) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ondansetron (CAS 99614-02-5) as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Ondansetron (CAS 99614-02-5) Sales by Region (2016-2021) & (Kg)
Table 16. Global Ondansetron (CAS 99614-02-5) Sales Market Share by Region (2016-2021)
Table 17. Global Ondansetron (CAS 99614-02-5) Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Ondansetron (CAS 99614-02-5) Sales by Country (2016-2021) & (Kg)
Table 19. North America Ondansetron (CAS 99614-02-5) Sales Market Share by Country (2016-2021)
Table 20. North America Ondansetron (CAS 99614-02-5) Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Ondansetron (CAS 99614-02-5) Revenue Market Share by Country (2016-2021)
Table 22. Europe Ondansetron (CAS 99614-02-5) Sales by Country (2016-2021) & (Kg)
Table 23. Europe Ondansetron (CAS 99614-02-5) Sales Market Share by Country (2016-2021)
Table 24. Europe Ondansetron (CAS 99614-02-5) Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Ondansetron (CAS 99614-02-5) Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Ondansetron (CAS 99614-02-5) Sales by Region (2016-2021) & (Kg)
Table 27. Asia Pacific Ondansetron (CAS 99614-02-5) Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Ondansetron (CAS 99614-02-5) Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Ondansetron (CAS 99614-02-5) Revenue Market Share by Region (2016-2021)
Table 30. Latin America Ondansetron (CAS 99614-02-5) Sales by Country (2016-2021) & (Kg)
Table 31. Latin America Ondansetron (CAS 99614-02-5) Sales Market Share by Country (2016-2021)
Table 32. Latin America Ondansetron (CAS 99614-02-5) Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Ondansetron (CAS 99614-02-5) Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Ondansetron (CAS 99614-02-5) Sales by Country (2016-2021) & (Kg)
Table 35. Middle East and Africa Ondansetron (CAS 99614-02-5) Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Ondansetron (CAS 99614-02-5) Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Ondansetron (CAS 99614-02-5) Revenue Market Share by Country (2016-2021)
Table 38. Global Ondansetron (CAS 99614-02-5) Sales (Kg) by Type (2016-2021)
Table 39. Global Ondansetron (CAS 99614-02-5) Sales Market Share by Type (2016-2021)
Table 40. Global Ondansetron (CAS 99614-02-5) Revenue (Million US$) by Type (2016-2021)
Table 41. Global Ondansetron (CAS 99614-02-5) Revenue Share by Type (2016-2021)
Table 42. Global Ondansetron (CAS 99614-02-5) Price (USD/Kg) by Type (2016-2021)
Table 43. Global Ondansetron (CAS 99614-02-5) Sales (Kg) by Application (2016-2021)
Table 44. Global Ondansetron (CAS 99614-02-5) Sales Market Share by Application (2016-2021)
Table 45. Global Ondansetron (CAS 99614-02-5) Revenue (Million US$) by Application (2016-2021)
Table 46. Global Ondansetron (CAS 99614-02-5) Revenue Share by Application (2016-2021)
Table 47. Global Ondansetron (CAS 99614-02-5) Price (USD/Kg) by Application (2016-2021)
Table 48. Qilu Pharma Corporation Information
Table 49. Qilu Pharma Description and Business Overview
Table 50. Qilu Pharma Ondansetron (CAS 99614-02-5) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 51. Qilu Pharma Ondansetron (CAS 99614-02-5) Product
Table 52. Qilu Pharma Recent Developments/Updates
Table 53. CSPC Corporation Information
Table 54. CSPC Description and Business Overview
Table 55. CSPC Ondansetron (CAS 99614-02-5) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 56. CSPC Ondansetron (CAS 99614-02-5) Product
Table 57. CSPC Recent Developments/Updates
Table 58. Fuan Pharma Corporation Information
Table 59. Fuan Pharma Description and Business Overview
Table 60. Fuan Pharma Ondansetron (CAS 99614-02-5) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 61. Fuan Pharma Ondansetron (CAS 99614-02-5) Product
Table 62. Fuan Pharma Recent Developments/Updates
Table 63. GSK Corporation Information
Table 64. GSK Description and Business Overview
Table 65. GSK Ondansetron (CAS 99614-02-5) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 66. GSK Ondansetron (CAS 99614-02-5) Product
Table 67. GSK Recent Developments/Updates
Table 68. PKU HealthCare Corporation Information
Table 69. PKU HealthCare Description and Business Overview
Table 70. PKU HealthCare Ondansetron (CAS 99614-02-5) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 71. PKU HealthCare Ondansetron (CAS 99614-02-5) Product
Table 72. PKU HealthCare Recent Developments/Updates
Table 73. Sino-Pharma Corporation Information
Table 74. Sino-Pharma Description and Business Overview
Table 75. Sino-Pharma Ondansetron (CAS 99614-02-5) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 76. Sino-Pharma Ondansetron (CAS 99614-02-5) Product
Table 77. Sino-Pharma Recent Developments/Updates
Table 78. Aosaikang Pharma Corporation Information
Table 79. Aosaikang Pharma Description and Business Overview
Table 80. Aosaikang Pharma Ondansetron (CAS 99614-02-5) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 81. Aosaikang Pharma Ondansetron (CAS 99614-02-5) Product
Table 82. Aosaikang Pharma Recent Developments/Updates
Table 83. Zhongbao Pharma Corporation Information
Table 84. Zhongbao Pharma Description and Business Overview
Table 85. Zhongbao Pharma Ondansetron (CAS 99614-02-5) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 86. Zhongbao Pharma Ondansetron (CAS 99614-02-5) Product
Table 87. Zhongbao Pharma Recent Developments/Updates
Table 88. Wockhardt Corporation Information
Table 89. Wockhardt Description and Business Overview
Table 90. Wockhardt Ondansetron (CAS 99614-02-5) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 91. Wockhardt Ondansetron (CAS 99614-02-5) Product
Table 92. Wockhardt Recent Developments/Updates
Table 93. Sun Pharma Corporation Information
Table 94. Sun Pharma Description and Business Overview
Table 95. Sun Pharma Ondansetron (CAS 99614-02-5) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 96. Sun Pharma Ondansetron (CAS 99614-02-5) Product
Table 97. Sun Pharma Recent Developments/Updates
Table 98. Aelida Healthcare Corporation Information
Table 99. Aelida Healthcare Description and Business Overview
Table 100. Aelida Healthcare Ondansetron (CAS 99614-02-5) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 101. Aelida Healthcare Ondansetron (CAS 99614-02-5) Product
Table 102. Aelida Healthcare Recent Developments/Updates
Table 103. Hospira Corporation Information
Table 104. Hospira Description and Business Overview
Table 105. Hospira Ondansetron (CAS 99614-02-5) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 106. Hospira Ondansetron (CAS 99614-02-5) Product
Table 107. Hospira Recent Developments/Updates
Table 108. Drums Healthcare Corporation Information
Table 109. Drums Healthcare Description and Business Overview
Table 110. Drums Healthcare Ondansetron (CAS 99614-02-5) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 111. Drums Healthcare Ondansetron (CAS 99614-02-5) Product
Table 112. Drums Healthcare Recent Developments/Updates
Table 113. SANDOZ Corporation Information
Table 114. SANDOZ Description and Business Overview
Table 115. SANDOZ Ondansetron (CAS 99614-02-5) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 116. SANDOZ Ondansetron (CAS 99614-02-5) Product
Table 117. SANDOZ Recent Developments/Updates
Table 118. Production Base and Market Concentration Rate of Raw Material
Table 119. Key Suppliers of Raw Materials
Table 120. Ondansetron (CAS 99614-02-5) Distributors List
Table 121. Ondansetron (CAS 99614-02-5) Customers List
Table 122. Ondansetron (CAS 99614-02-5) Market Trends
Table 123. Ondansetron (CAS 99614-02-5) Growth Drivers
Table 124. Ondansetron (CAS 99614-02-5) Market Restraints
Table 125. Global Ondansetron (CAS 99614-02-5) Sales Forecast by Type (2022-2027) & (Kg)
Table 126. Global Ondansetron (CAS 99614-02-5) Sales Market Share Forecast by Type (2022-2027)
Table 127. Global Ondansetron (CAS 99614-02-5) Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 128. Global Ondansetron (CAS 99614-02-5) Revenue Market Share Forecast by Type (2022-2027)
Table 129. Global Ondansetron (CAS 99614-02-5) Sales Forecast by Application (2022-2027) & (Kg)
Table 130. Global Ondansetron (CAS 99614-02-5) Sales Market Share Forecast by Application (2022-2027)
Table 131. Global Ondansetron (CAS 99614-02-5) Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 132. Global Ondansetron (CAS 99614-02-5) Revenue Market Share Forecast by Application (2022-2027)
Table 133. Global Ondansetron (CAS 99614-02-5) Sales Forecast by Region (2022-2027) & (Kg)
Table 134. Global Ondansetron (CAS 99614-02-5) Sales Market Share Forecast by Region (2022-2027)
Table 135. Global Ondansetron (CAS 99614-02-5) Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 136. Global Ondansetron (CAS 99614-02-5) Revenue Market Share Forecast by Region (2022-2027)
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Ondansetron (CAS 99614-02-5)
Figure 2. Global Ondansetron (CAS 99614-02-5) Market Share by Type in 2020 & 2027
Figure 3. Ondansetron Hydrochloride Tablets Product Picture
Figure 4. Ondansetron Hydrochloride Capsule Product Picture
Figure 5. Ondansetron Hydrochloride Injection Product Picture
Figure 6. Others Product Picture
Figure 7. Global Ondansetron (CAS 99614-02-5) Market Share by Application in 2020 & 2027
Figure 8. Hospital Pharmacies
Figure 9. Retail Pharmacies
Figure 10. Online Pharmacies
Figure 11. Global Ondansetron (CAS 99614-02-5) Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Ondansetron (CAS 99614-02-5) Market Size 2016-2027 (US$ Million)
Figure 13. Global Ondansetron (CAS 99614-02-5) Sales 2016-2027 (Kg)
Figure 14. Global Ondansetron (CAS 99614-02-5) Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 15. Ondansetron (CAS 99614-02-5) Sales Share by Manufacturers in 2020
Figure 16. Global Ondansetron (CAS 99614-02-5) Revenue Share by Manufacturers in 2020
Figure 17. The Global 5 and 10 Largest Ondansetron (CAS 99614-02-5) Players: Market Share by Revenue in 2020
Figure 18. Ondansetron (CAS 99614-02-5) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 19. Global Ondansetron (CAS 99614-02-5) Sales Market Share by Region (2016-2021)
Figure 20. Global Ondansetron (CAS 99614-02-5) Sales Market Share by Region in 2020
Figure 21. Global Ondansetron (CAS 99614-02-5) Revenue Market Share by Region (2016-2021)
Figure 22. Global Ondansetron (CAS 99614-02-5) Revenue Market Share by Region in 2020
Figure 23. U.S. Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. Canada Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Germany Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. France Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. U.K. Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Italy Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Russia Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. China Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Japan Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. South Korea Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. India Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Australia Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Taiwan Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Indonesia Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Thailand Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Malaysia Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Philippines Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Vietnam Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Mexico Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Brazil Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Argentina Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Turkey Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Saudi Arabia Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. U.A.E Ondansetron (CAS 99614-02-5) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. Sales Market Share of Ondansetron (CAS 99614-02-5) by Type (2016-2021)
Figure 48. Sales Market Share of Ondansetron (CAS 99614-02-5) by Application (2016-2021)
Figure 49. Sales Market Share of Ondansetron (CAS 99614-02-5) by Application in 2020
Figure 50. Revenue Share of Ondansetron (CAS 99614-02-5) by Application (2016-2021)
Figure 51. Revenue Share of Ondansetron (CAS 99614-02-5) by Application in 2020
Figure 52. Manufacturing Cost Structure of Ondansetron (CAS 99614-02-5)
Figure 53. Manufacturing Process Analysis of Ondansetron (CAS 99614-02-5)
Figure 54. Ondansetron (CAS 99614-02-5) Industrial Chain Analysis
Figure 55. Channels of Distribution
Figure 56. Distributors Profiles
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
